Biotech ETF (BBH) Hits New 52-Week High
- VanEck Biotech ETF BBH Hits 52-Week High: The ETF has reached a 52-week high and surged 21.4% from its low.
- Outlook on the ETF: Investors are looking at the potential for more gains in the near future.
- Composition of the ETF: The fund tracks the MVIS US Listed Biotech 25 Index, focusing on companies involved in genetic analysis and drug development.
- Amgen Stock Influence: Amgen stock makes up 17% of the BBH fund, showing strong performance recently due to positive data on a weight loss injection.
- Positive Forecast: BBH has a Zacks ETF Rank #2 (Buy) and a positive weighted alpha, indicating a possible further rally in the near term.
Trade with 70% Backtested Accuracy
Analyst Views on BBH
No data
About the author
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
Company Overview: Vertex Pharmaceuticals, with a market cap of $118.7 billion, focuses on innovative therapies for cystic fibrosis and rare diseases, reporting a 15.7% revenue growth in Q4 to $2.91 billion, though adjusted EPS fell short of expectations.
Stock Performance and Analyst Ratings: Despite underperforming the broader market over the past year, VRTX has seen a positive outlook from analysts, with a consensus rating of "Moderate Buy" and a raised price target reflecting strong sales expectations in cystic fibrosis.
VanEck Announces Year-End Distributions for VanEck Equity ETFs
VanEck ETF Distributions: VanEck announced the 2024 annual distributions per share for its equity exchange-traded funds (ETFs), with various funds providing specific income amounts and capital gains, payable on December 24, 2024.
Investment Risks and Tax Information: The distributions will primarily come from net investment income, with potential variations in future payments. Investors are advised to seek independent tax advice and review the prospectus for detailed information on risks associated with investing in VanEck ETFs.
Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?
Company Performance: Vertex Pharmaceuticals has shown strong stock performance, gaining 32.7% over the past year, outperforming both the S&P 500 and the VanEck Biotech ETF, driven by successful product launches and anticipated FDA decisions.
Analyst Ratings and Forecasts: The consensus among analysts is a "Moderate Buy" for VRTX, with a mean price target of $520.48, indicating potential upside, while RBC Capital maintains a "Hold" rating with a price target of $451.
Should You Invest in the VanEck Biotech ETF (BBH)?
Overview of VanEck Biotech ETF (BBH): The VanEck Biotech ETF, launched in 2011, offers low-cost, diversified exposure to the Healthcare - Biotech sector, with a focus on companies involved in drug development and genetic analysis. It has assets over $457 million and an annual operating expense of 0.35%.
Performance and Rankings: As of August 2024, BBH has gained approximately 12.54% over the past year, holds a Zacks ETF Rank of 2 (Buy), and is considered a high-risk investment due to its concentrated holdings and beta of 0.74.
Biotech ETF (BBH) Hits New 52-Week High
- VanEck Biotech ETF BBH Hits 52-Week High: The ETF has reached a 52-week high and surged 21.4% from its low.
- Outlook on the ETF: Investors are looking at the potential for more gains in the near future.
- Composition of the ETF: The fund tracks the MVIS US Listed Biotech 25 Index, focusing on companies involved in genetic analysis and drug development.
- Amgen Stock Influence: Amgen stock makes up 17% of the BBH fund, showing strong performance recently due to positive data on a weight loss injection.
- Positive Forecast: BBH has a Zacks ETF Rank #2 (Buy) and a positive weighted alpha, indicating a possible further rally in the near term.
Should You Invest in the VanEck Biotech ETF (BBH)?
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
Company Overview: Vertex Pharmaceuticals, with a market cap of $118.7 billion, focuses on innovative therapies for cystic fibrosis and rare diseases, reporting a 15.7% revenue growth in Q4 to $2.91 billion, though adjusted EPS fell short of expectations.
Stock Performance and Analyst Ratings: Despite underperforming the broader market over the past year, VRTX has seen a positive outlook from analysts, with a consensus rating of "Moderate Buy" and a raised price target reflecting strong sales expectations in cystic fibrosis.
VanEck Announces Year-End Distributions for VanEck Equity ETFs
VanEck ETF Distributions: VanEck announced the 2024 annual distributions per share for its equity exchange-traded funds (ETFs), with various funds providing specific income amounts and capital gains, payable on December 24, 2024.
Investment Risks and Tax Information: The distributions will primarily come from net investment income, with potential variations in future payments. Investors are advised to seek independent tax advice and review the prospectus for detailed information on risks associated with investing in VanEck ETFs.
Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?
Company Performance: Vertex Pharmaceuticals has shown strong stock performance, gaining 32.7% over the past year, outperforming both the S&P 500 and the VanEck Biotech ETF, driven by successful product launches and anticipated FDA decisions.
Analyst Ratings and Forecasts: The consensus among analysts is a "Moderate Buy" for VRTX, with a mean price target of $520.48, indicating potential upside, while RBC Capital maintains a "Hold" rating with a price target of $451.
Should You Invest in the VanEck Biotech ETF (BBH)?
Overview of VanEck Biotech ETF (BBH): The VanEck Biotech ETF, launched in 2011, offers low-cost, diversified exposure to the Healthcare - Biotech sector, with a focus on companies involved in drug development and genetic analysis. It has assets over $457 million and an annual operating expense of 0.35%.
Performance and Rankings: As of August 2024, BBH has gained approximately 12.54% over the past year, holds a Zacks ETF Rank of 2 (Buy), and is considered a high-risk investment due to its concentrated holdings and beta of 0.74.
Biotech ETF (BBH) Hits New 52-Week High
- VanEck Biotech ETF BBH Hits 52-Week High: The ETF has reached a 52-week high and surged 21.4% from its low.
- Outlook on the ETF: Investors are looking at the potential for more gains in the near future.
- Composition of the ETF: The fund tracks the MVIS US Listed Biotech 25 Index, focusing on companies involved in genetic analysis and drug development.
- Amgen Stock Influence: Amgen stock makes up 17% of the BBH fund, showing strong performance recently due to positive data on a weight loss injection.
- Positive Forecast: BBH has a Zacks ETF Rank #2 (Buy) and a positive weighted alpha, indicating a possible further rally in the near term.
Should You Invest in the VanEck Biotech ETF (BBH)?
